about
Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fightTriple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)Oral glycoprotein IIb/IIIa inhibitors: why don't they work?Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic eventsAspirin dose and six-month outcome after an acute coronary syndromeAnalysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trialsMeta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stentingAmplified benefit of clopidogrel versus aspirin in patients with diabetes mellitusAspirin and clopidogrel resistance: an emerging clinical entityScientific and therapeutic advances in antiplatelet therapyClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsClopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stentingPatients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialClopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialLack of evidence of a clopidogrel-statin interaction in the CHARISMA trialAn analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialSafety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.Need to test the arterial inflammation hypothesis.Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with HeightUsing C-reactive protein to assess cardiovascular disease risk.Predictive value of high sensitivity C-reactive protein in the diagnosis and outcomes of acute aortic syndromesDesign and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial FiThe relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and AvoidanceStudy of young patients with myocardial infarction: Design and rationale of the YOUNG-MI Registry.Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials.Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.Variability in platelet responsiveness to clopidogrel among 544 individuals.The future--panel discussion.A heart within a heart.An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial.Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
P50
Q24799198-DC68ABCF-FA67-466C-AE72-EC2242E19E24Q28165540-9CB6F2BE-2D38-4E83-8459-3184EF44AEE9Q28166805-0CC3F9D3-806B-4838-A2F8-4EBED378812CQ28166894-AEC7A511-1261-427D-8430-E042FDC2F62AQ28167843-64B922A5-0CE7-4625-9FBF-491C86EB5C7CQ28174968-7D4087E6-3EF7-43A7-AF98-E8876DD1464BQ28191931-216DC3D2-252B-47C2-9D73-B921F86D8A2FQ28193753-6126E45C-E2F5-4920-B1A0-510CF11E0794Q28194021-CB270CA9-8908-4B95-A246-74EEDDA624E0Q28194547-28FE690C-6E58-4AC0-86D8-C2F8F54EF798Q28195656-E7D946BC-AC09-45DC-B7FA-ADD49F0F36B8Q28199180-31D5D2F2-C427-429D-A40C-835C46442BAEQ28210537-681BB6CF-D69F-45BB-993E-E18039419E19Q28210890-FDE60E29-3E68-4BE1-97F2-490825B1EA2DQ28218952-EC27B827-5DD1-48B7-9FB8-E43B97179A3EQ28219113-9B0735BB-6C93-4CA8-9753-27E703708708Q33342386-357A622E-88D0-4509-9C19-3C62DC4C6DBBQ33578422-E982634D-73BE-40BA-91E7-16E04C82B521Q33621896-8EFAF259-5571-4843-AA44-4F06570BC48CQ33658002-767D98B4-91FC-4604-A53E-302460C49644Q34136541-2F234FB2-798A-47A7-A96E-AB074AFD8BE0Q34458862-F8ED2430-F69F-4771-83F1-944475B6BB95Q35185608-300D8392-E50C-4E1F-B285-1FC48BDB412CQ36982556-A1AA50BE-649F-4888-9E64-11D01DB80845Q37412869-2DB28C2E-56AC-4B8A-89A5-1B7025D39615Q37631913-46424B90-26B9-4FC3-BC6F-33151AE4103BQ38370738-0BB5645B-1D84-43AD-9873-A6F020B122B8Q38373039-1E3F7708-F76E-4740-82D5-79746D0BB386Q38626009-27A1EA69-E093-4ABF-B3E3-8094F9B17D45Q39307630-334E3B00-C105-4673-BB39-DD30648FA861Q39428436-C38E2CAD-369A-4B7C-8FEE-166126CC401DQ39550267-D8B6AE48-AF3E-4D1D-943E-C324B867F90AQ40454244-6C2B4045-EEC5-4EA6-BADF-8014194BFAD8Q40499998-31963B0E-8ADD-4C98-92E1-B890B49C03EFQ41495411-163B8BC6-1CE1-4477-ACE7-0AFEBA0054F6Q42694751-3B7A30FD-F1D4-4A68-9CB6-EE2EB005170CQ42994151-E3BEE82C-53DD-498A-B66E-F3C3BD0DBFD1Q43296148-F8AA9CD2-AB90-4E54-BA01-FA6EDAF862E2Q43494102-B425C633-46D2-414C-95A9-AB55954DBE35Q44243294-CECE04FA-9214-4AF3-B388-01F473407E50
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Deepak L Bhatt
@es
Deepak L. Bhatt
@en
Deepak L. Bhatt
@nl
Deepak L. Bhatt
@sl
type
label
Deepak L Bhatt
@es
Deepak L. Bhatt
@en
Deepak L. Bhatt
@nl
Deepak L. Bhatt
@sl
prefLabel
Deepak L Bhatt
@es
Deepak L. Bhatt
@en
Deepak L. Bhatt
@nl
Deepak L. Bhatt
@sl
P214
P106
P1153
7102974175
P1580
P21
P214
P31
P3835
deepak-l-bhatt
P496
0000-0002-1278-6245
P569
2000-01-01T00:00:00Z
P735
P7859
lccn-nb2003084748